Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.83 ▲ +0.01
(+1.03%)
MKT CAP: $31.4M • VOL: 72.0K
52W L $1 52W H $3
MGX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $25.2M | $52.3M | $44.8M |
| YoY Revenue Growth % | -51.8% | +16.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$96.0M | -$88.9M | -$78.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$87.9M | -$78.1M | -$68.3M |
| EBITDA (Normalized) | -$95.6M | -$86.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$88.9M | -$109.1M | -$91.4M |
| Capital Expenditures (CapEx) | $574.0K | $3.1M | — |
| Free Cash Flow (FCF) | -$89.5M | -$112.2M | -$91.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -33.9% | — |
| Cash & Short-Term Equivalents | $41.7M | $27.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $158.6M | $234.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MGX.